SCHEMBL6913121

SCHEMBL6913121

CC(C)(C)OC(=O)N1CC(=Cc2nc(-c3ccc(F)cc3)cs2)C1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
MAPK1 P28482 1/20 0.44
ENPP2 Q13822 5/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
ALDH1A1 P00352 1/20 0.41
USP30 Q70CQ3 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
F2RL1 P55085 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2226449 0.83 LMNA (0.43) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL17296111 0.76 HDAC1 (0.45) MAPK1MEN1KMT2A
SCHEMBL3767565 0.76 MAPT (0.74) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL3614966 0.75 RAB9A (0.48) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL3614967 0.75 RAB9A (0.48) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL3767361 0.74 ENPP2 (0.57) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL6913478 0.74 L3MBTL1 (0.53) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL22462811 0.72 L3MBTL1 (0.56) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL6913568 0.72 TRPV1 (0.52) SMN1; SMN2MAPTLMNAHTTMAPK1
SCHEMBL23830691 0.69 ABHD6 (0.39) MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
WO-2011088192-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289495-A1 COMPOUNDS AND METHODS XDH, CCNY, TOP2B SMN1; SMN2 2921/4885MAPT 4489/4885LMNA 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.